Pharmacokinetics of N-n-butyl haloperidol iodide determined by HPLCMS method in rabbits

Abstract

Abstract: AIM: To study pharmacokinetics of N-nbutyl haloperidol iodide (F2) in rabbits.METHODS: Blood samples were collected at different time points after six rabbits were given F2 2.0 mg·kg^-1, iv.Then the plasma concentrations of F2 were detected by HPLC-MS method.And pharmacokinetic parameters were calculated using the 3p97 program.RESULTS AND CONCLUSION: The open two-compartment model can best describe the concentration-time curve of F2.The major pharmacokinetic parameters are listed as following:the half-life of distribution phase T_12α=0.10 h, the half-life of elimination phase Σ_12β=6.4 h, the volume of the central compartment Vc=4 L, the total areas under the concentration-time curve AUC=183 μg·h^-1·L^-1, and the plasma clearance CL=12.9 L·h^-1.HPLC-MS is a sensitive and specific method in this study.

Key words: N-n-butyl Haloperidol Iodide (F2 ), rabbit, pharmacokinetics, HPLC-MS

CLC Number:

R969.1

LIN Chao-Xian, SHI Gang-Gang, LUO Wen-Hong, LI Hui, ZHENG Jin-Hong, GAO Fen-Fei. Pharmacokinetics of N-n-butyl haloperidol iodide determined by HPLCMS method in rabbits[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(8): 922-924.

References

1 石刚刚, 郑锦鸿, 李长潮.氟哌啶醇季铵盐衍生物对冠状动脉作用的研究[J].中国药学杂志, 1998;33(9):529-31
2 韦日生, 石刚刚.氟哌啶醇季铵盐衍生物对猪冠状动脉螺旋条作用机制的探讨[J].中国新药杂志, 2000;9(11):761-3
3 樊化平, 石刚刚, 郑锦鸿.氟哌啶醇季铵盐衍生物对大鼠胸主动脉螺旋肌条收缩的影响[J].汕头大学医学院学报, 2003;16(2):67-9
4 庄学煊, 陈少刚, 黄展勤, 石刚刚.氟哌啶醇季铵盐衍生物对大鼠急性心肌缺血的保护作用[J].汕头大学医学院学报, 2001;14(3):172-6
5 Huang ZQ, Shi GG, Chen CY.Protective effect of quaternary ammonium salt derivative (F2) of haloperidol on ischemia and reperfusion injury in rat heart[J].J Shantou Univ Medi Coll,2002;15(1):3-7
6 高分飞, 石刚刚, 郑锦鸿.碘化正丁基氟哌啶醇对兔心肌缺血再灌注损伤血流动力学和心肌组织中酶的影响[J].中国药理学通报, 2003;19(5):559-62
7 韦日生, 石刚刚, 张映娜.氟哌啶醇季铵盐衍生物对血管平滑肌细胞钙离子的影响[J].中国药理学通报,2001;17(1):54-6
8 Huang ZQ, Shi GG, Zheng JH, Chen CY, Wu XI.Effects of N-n-butyl haloperidol iodide on rat myocardial ischemia and reperfusion injury and L-type calcium currect[J].Acta Pharmacol Sin, 2003;24(8):757-63
9 韦日生, 石刚刚.碘化正丁基氟哌啶醇对大鼠胸主动脉平滑肌钾通道作用的研究[J].中国药理学通报, 2001;17(5):551-5
10 樊化平, 石刚刚, 罗文鸿, 李慧, 郑锦鸿, 高分飞.碘化正丁基氟哌啶醇在大鼠的药代动力学研究及组织分布[J].中国药理学通报, 2004;20(3);273-5
11 Cheng YF, Paalzow LK.Linear pharmacokinetics of haloperidol in the rat[J].Biopharm Drug Dispos, 1992;13(1):69-76
12 中国药典委员会.临床用药须知[M].北京:化学工业出版社, 1995 :76
13 Gorrod JW, Fang J.On the metabolism of haloperidol[J].Xenobiotica, 1993;23(5):495-508

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[3]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[4]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[5]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[6]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[7]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[8]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[9]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[10]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[11]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[12]	DAI Jingyi, WANG Jingjing, ZHANG Jing, YU Jicheng, LI Nanyang, HUANG Zhiwei. Clinical application and research progress of inhaled methoxyflurane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 808-813.
[13]	PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525.
[14]	WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.
[15]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.